In vitro-In Vivo Correlations: Tricks and Traps

被引:84
作者
Cardot, J. -M. [1 ]
Davit, B. M. [2 ]
机构
[1] Auvergne Univ, UFR Pharm, ERT CIDAM, Dept Biopharmaceut, F-63001 Clermont Ferrand, France
[2] US FDA, Div Bioequivalence 2, Off Gener Drugs, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
来源
AAPS JOURNAL | 2012年 / 14卷 / 03期
关键词
biowaiver; in vitro-in vivo correlation (IVIVC); predictability; prediction; time scaling; ORAL-DRUG ABSORPTION; IVIVC; LEVEL; MODEL; DISSOLUTION; FORMULATION; SYSTEM;
D O I
10.1208/s12248-012-9359-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro-in vivo correlation (IVIVC) is a biopharmaceutical tool recommended to be used in development of formulation. When validated, it can speed up development of formulation, be used to fix dissolution limits and also as surrogate of in vivo study. However, as do all tools, it presents limitations and traps. The aim of the present paper is to investigate five common traps which could limit either the setting or use of IVIVC (1) using mean or individual values; (2) correction of absolute bioavailability; (3) correction of lag time and time scaling; (4) flip-flop model; and (5) predictability corrections.
引用
收藏
页码:491 / 499
页数:9
相关论文
共 38 条
[21]  
Gillespie WR, 1997, ADV EXP MED BIOL, V423, P53
[22]  
Hemmingsen Pernille H, 2011, Pharmaceutics, V3, P73, DOI 10.3390/pharmaceutics3010073
[23]  
ICH Steering Committee, 2009, DRAFT CONS GUID DEV
[24]   Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series [J].
Kortejarvi, H. ;
Malkki, J. ;
Marvola, M. ;
Urtti, A. ;
Yliperttula, M. ;
Pajunen, P. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (07) :1595-1605
[25]   Human intestinal permeability [J].
Lennernäs, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (04) :403-410
[26]   Modern bioavailability, bioequivalence and biopharmaceutics classification system.: New scientific approaches to international regulatory standards [J].
Löbenberg, R ;
Amidon, GL .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :3-12
[27]   A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals [J].
Martinez, MN ;
Amidon, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (06) :620-643
[28]   Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet® constant-release drug delivery system [J].
Marvola, J ;
Kanerva, H ;
Slot, L ;
Lipponen, M ;
Kekki, T ;
Hietanen, H ;
Mykkänen, S ;
Ariniemi, K ;
Lindevall, K ;
Marvola, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 281 (1-2) :3-10
[29]  
Mauger D T, 1997, J Biopharm Stat, V7, P565, DOI 10.1080/10543409708835207
[30]  
NIHS, 2006, GUID BIOEQ STUD GEN